Biagio Ricciuti, MD
Staff Scientist II - MD at Dana-Farber Cancer Institute
With the support of the ILCF, we have demonstrated that genomically defined subset of lung cancers
harboring mutations in genes involved in DNA damage repair (DDR) derive improved clinical outcomes
with PD-(L)1 blockade.